bluebird bio is ready to fly in the faces of rare genetic diseases. The company is using gene therapy to develop orphan drugs for two rare diseases. Its lead drug candidate, Lenti-D, is being developed to treat childhood cerebral adrenoleukodystrophy (CCALD), a rare neurological disorder that affects boys. Its second drug candidate, LentiGlobin, is being developed to treat the blood disorders beta-thalassemia major and sickle cell disease. Both drugs will begin studies by 2014. In addition, bluebird bio partnered with
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Essential information for a successful call
- EMPLOYEES (This Site) 96
- EMPLOYEES (All Sites) 1090
- ASSETS (MIL USD) 1727.424
- SALES (MIL USD) 44.674
- TICKER SYMBOL BLUE
- Incorporated 1992
- FISCAL YEAR END DEC
Get in Touch with 23 Contacts
DANIEL S LYNCHChairman of the Board
SUSANNA HIGHChief Operating Officer
JEFFREY T WALSHChief Financial Officer and Officer